title: Therapeutic leukapheresis: 9-year experience in a University Hospital.
abstract: BACKGROUND
  Hyperleucocytosis is associated with higher morbidity and mortality related to possible development of leucostasis, tumour lysis syndrome and/or disseminated intravascular coagulation. There is insufficient evidence of the need for leukocytapheresis during early treatment of hyperleucocytosis, and its efficiency remains controversial, although leucoreduction is a measure that can prevent adverse events and death. The aim of this study was to analyse the safety and effectiveness of therapeutic leukocytapheresis and its influence on early mortality in our case series, adjusted to independent mortality risk factors described in the literature.
  
  
  METHODS
  This was a retrospective review (June 2003-June 2012) of procedures carried out for the treatment of hyperleucocytosis at the Haematology and Haemotherapy Service of Miguel Servet University Hospital. The patients' data and technical information were prospectively registered for each leukocytapheresis session.
  
  
  RESULTS
  Thirteen patients underwent a total of 27 leukocytapheresis procedures. After an average of two sessions, a statistically significant drop in the initial leucocyte counts was observed (p<0.01), as well as a relevant drop in lactate dehydrogenase levels. The only analytical value statistically related to early mortality in univariate analysis was initial creatinine level greater than 1.2 mg/dL (p=0.012, OR=2.5).
  
  
  CONCLUSIONS
  Despite the small size and limited homogeneity of our case series, we can conclude that leukocytapheresis is a safe and effective therapeutic measure for leucoreduction in haematological pathologies of any lineage, particularly in patients without acute myeloid leukaemia. Patients with acute myeloid leukaemia had worse outcomes within 6 months of having finished leukocytapheresis sessions, as well as in terms of mean global survival and mean time of mortality. However, global mortality rates were similar in patients with or without acute myeloid leukaemia.
authors: Haematology Department, Miguel Servet University Hospital, Zaragoza, Spain.
authors: Ingrid M
authors: IM
authors: Parra Salinas
authors: Haematology Department, Miguel Servet University Hospital, Zaragoza, Spain.
authors: Victoria P
authors: VP
authors: González Rodriguez
authors: Haematology Department, San Jorge Hospital, Huesca, Spain.
authors: José A
authors: JA
authors: García-Erce
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003404:Creatinine / Q000097:blood; D018572:Disease-Free Survival; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007937:Leukapheresis; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000401:mortality / Q000628:therapy; D007964:Leukocytosis / Q000097:blood / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000401:mortality / Q000628:therapy
chemical_list: D003404:Creatinine; D007770:L-Lactate Dehydrogenase